# IMMUNOPRESERVE (NCT03702179)

> Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach

No report yet. It can be ordered.

- Drugs tested: durvalumab plus tremelimumab plus radiotherapy
- Indication: localized muscle-invasive bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03702179
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Spanish Oncology Genito-Urinary Group
- Conditions: Invasive Bladder Cancer
- Interventions: Durvalumab; Tremelimumab; Radiotherapy
- Enrollment: 32
- Primary outcome: Proportion of Patients With Pathological Response

## Indexed commentary on IMMUNOPRESERVE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=immunopreserve-nct03702179